Faeth Therapeutics grants director 25K options
A Faeth Therapeutics director was granted options for 25,000 shares vesting monthly over three years.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Faeth Therapeutics, Inc. (FTH) reported that director Karen H. Vousden received a stock option grant for 25,000 shares of common stock on September 11, 2026. The option has an exercise price of $37.44 per share, expires on September 10, 2036, and vests in 36 equal monthly installments through September 11, 2029, contingent on her continued service. No transactions were reported under a Rule 10b5-1 trading plan.
Insider Trade Summary
Grant/Award: 25,000 shares
Grant/Award
1 txn
Insider
Vousden Karen H
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) F1 | 25,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 25,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or September 11, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
Key Figures
Option shares granted: 25,000 shares
Exercise price: $37.44 per share
Shares underlying option after grant: 25,000 shares
+2 more
5 metrics
Option shares granted
25,000 shares
Stock option award to director Karen H. Vousden on September 11, 2026
Exercise price
$37.44 per share
Exercise price of the stock option covering 25,000 shares
Shares underlying option after grant
25,000 shares
Total option position reported following the transaction
Vesting schedule
36 monthly installments over 3 years
Vesting from September 11, 2026 until fully vested on September 11, 2029
Option expiration date
September 10, 2036
Final date on which the granted options may be exercised
Key Terms
Stock option, exercise price, vesting, Common Stock
4 terms
Stock option financial
"reported that Karen H. Vousden received a stock option grant for 25,000 shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"The option has an exercise price of $37.44 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to the option vest and become exercisable in 36 equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying security is Faeth Therapeutics Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Faeth Therapeutics (FTH) report for Karen H. Vousden?
Faeth Therapeutics reported that director Karen H. Vousden received a stock option grant for 25,000 shares of common stock on September 11, 2026, as equity compensation rather than a market purchase or sale.
What is the exercise price of the new stock options reported by FTH?
The stock options granted to Karen H. Vousden have an exercise price of $37.44 per share for Faeth Therapeutics common stock, meaning she can buy up to 25,000 shares at that price once the options vest and are exercisable.
How do the Faeth Therapeutics options granted to Karen H. Vousden vest?
The options vest and become exercisable in 36 equal monthly installments over three years, so they are fully vested on September 11, 2029, provided Karen H. Vousden continues serving the company on each vesting date.
When do Karen H. Vousden’s Faeth Therapeutics options expire?
The options granted to Karen H. Vousden expire on September 10, 2036. After that date, any unexercised portion of the 25,000-share stock option will no longer be exercisable.
Were the FTH insider options granted under a Rule 10b5-1 trading plan?
No. The filing indicates that the transactions were not made under a Rule 10b5-1 trading plan, meaning they were not executed pursuant to a pre-arranged trading program under that rule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
